EUVIMEDEUVIMED entdecken
Crossref

Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma

Jun Aoyama, Yusuke Nojima, Daisuke Sano iD, Yuri Hirai, Natsumi Kijima, Yoshihiro Aizawa, Kentaro Takada, Takashi Hatano, Hideaki Takahashi iD, Goshi Nishimura, Nobuhiko Oridate

Head & Neck · 2023-07 · 45 (7) · 1801-1811

DOI: 10.1002/hed.27395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 15.05.2023. Verfasst von Jun Aoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Carcinoma, Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously established a patient‐derived xenograft (PDX) model, patient‐derived organoids (PDOs), and PDX‐derived organoids (PDXOs) for salivary duct carcinoma (SDC). Using these models, this study examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2‐positive SDC.

Methods

The therapeutic effect of lapatinib was assessed in SDC PDXOs with regards to cell growth, receptor/downstream signaling molecule expression, phosphorylation levels, and apoptosis. Effect of lapatinib treatment was evaluated in vivo in SDC PDX mice.

Results

The siRNA knockdown of HER2 and lapatinib suppressed cell proliferation in SDC PDXOs. Lapatinib inhibited the phosphorylation of HER2 and its downstream targets, and induced apoptosis in SDC PDXOs. Lapatinib also significantly reduced tumor volumes compared with that of the control in SDC PDX mice.

Conclusion

For the first time, we demonstrated the efficacy of anti‐HER2 therapy in HER2‐positive SDC using preclinical models of SDC PDX and PDXO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salivary Gland NeoplasmsCarcinoma, DuctalHumansAnimalsMiceLapatinibSalivary DuctsErb-b2 Receptor Tyrosine KinasesSignal Transduction

Stichwörter der Autor:innen

HER2lapatinibpatient-derived organoidsalivary duct carcinomasalivary gland cancer

Substanzen

LapatinibErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.

ORCID-Profile: Daisuke Sano, Hideaki Takahashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Aoyama, J., Nojima, Y., Sano, D., Hirai, Y., Kijima, N., Aizawa, Y., Takada, K., Hatano, T., Takahashi, H., Nishimura, G., & Oridate, N. (2023). Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma. Head & Neck, 45(7), 1801-1811. https://doi.org/10.1002/hed.27395

Vancouver

Aoyama J, Nojima Y, Sano D, Hirai Y, Kijima N, Aizawa Y, et al. Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma. Head & Neck. 2023;45(7):1801-1811. doi:10.1002/hed.27395

BibTeX
@article{Aoyama2023,
  author = {Aoyama, Jun and Nojima, Yusuke and Sano, Daisuke and Hirai, Yuri and Kijima, Natsumi and Aizawa, Yoshihiro and Takada, Kentaro and Hatano, Takashi and Takahashi, Hideaki and Nishimura, Goshi and Oridate, Nobuhiko},
  title = {Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma},
  journal = {Head & Neck},
  year = {2023},
  volume = {45},
  number = {7},
  pages = {1801--1811},
  doi = {10.1002/hed.27395}
}
Kostenlos starten →